Publicly funded research leads to the development of many new drugs, but the profits are largely reaped by big pharmaceutical companies through exclusive licensing deals, mergers and acquisitions, which can reduce competition and patients’ access to medicines.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Galkina Cleary, E. et al. Proc. Natl Acad. Sci. USA 115, 2329–2334 (2018).
Cunningham, C. et al. J. Polit. Econ. 129, 649–702 (2021).
IQVIA MIDAS Database (accessed 30 November 2021).
Patridge, E. V. et al. Drug Discov. Today 20, 1182–1187 (2015).
Sampat, B. N. et al. Health Aff. 30, 332–339 (2011).
KEI. https://www.keionline.org/car (accessed 30 November 2021).
Schlander, M. et al. Ann. Oncol. 31, S966 (2020).
Gilead Sciences. https://investors.gilead.com/node/38091/html (2021).
FDA. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices (2019).
Stern, A. D. et al. Health Aff. 40, 989–999 (2021).
Bennette, C. S. et al. Health Aff. 35, 805–812 (2016).
FiercePharma. https://www.fiercepharma.com/pharma/abbvie-s-new-pan-genotypic-hep-c-drug-mavyret-undercuts-competition (2017).
Caffarra, C. et al. https://voxeu.org/content/how-tech-rolls-potential-competition-and-reverse-killer-acquisitions (2020).
Love, J. Knowledge Ecology International https://www.keionline.org/26456 (2018).
Ledley, F. D. et al. JAMA 323, 834 (2020).
Anderson, R. BBC News https://www.bbc.com/news/business-28212223 (2014).
Statista. https://www.statista.com/statistics/965888/number-biotechnology-pharmaceutical-manda-deals/ (2022).
Liu, M., Feldman, W.B., Avorn, J. & Kesselheim. Health Affairs Forefront https://www.healthaffairs.org/do/10.1377/hblog20200501.798711/full/ (2020).
Novartis Inc. https://www.novartis.com/sites/novartis_com/files/novartis-20-f-2020.pdf (2021).
Novartis Inc. https://www.novartis.com/sites/novartis_com/files/novartis-20-f-2018.pdf (2019).
Gilead Sciences. https://investors.gilead.com/node/36541/html (2019).
AdisInsight. https://adisinsight.springer.com (accessed 30 November 2021).
Acknowledgements
This study was funded by the Swiss National Science Foundation (SNSF).
Author information
Authors and Affiliations
Contributions
Both authors conceptualized the comment. M.N. wrote the first draft. K.N.V. revised and finalized the draft.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Newham, M., Vokinger, K.N. Adverse effects of acquisitions in the pharmaceutical industry. Nat Med 28, 1342–1344 (2022). https://doi.org/10.1038/s41591-022-01784-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01784-5
This article is cited by
-
Approval and therapeutic value of gene therapies in the US and Europe
Gene Therapy (2023)